Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Young Kwang Chae*, Ayush Arya, Lauren Chiec, Hiral Shah, Ari Rosenberg, Sandip Patel, Kirtee Raparia, Jaehyuk Choi, Derek A. Wainwright, Victoria Villaflor, Massimo Cristofanilli, Francis Giles

*Corresponding author for this work

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Molecular techniques have improved our understanding of the pathogenesis of cancer development. These techniques have also fueled the rational development of targeted drugs for patient populations stratified by their genetic characteristics. These novel methods have changed the classic paradigm of diagnostic pathology; among them are IHC, FISH, polymerase chain reaction (PCR) and microarray technology. IHC and FISH detection methods for human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR) and programmed death ligand-1 (PD-L1) were recently approved by the Food and Drug Administration (FDA) as routine clinical practice for cancer patients. Here, we discuss general challenges related to the predictive power of these molecular biomarkers for targeted therapy in cancer medicine. We will also discuss the prospects of utilizing new biomarkers for fibroblast growth factor receptor (FGFR) and hepatocyte growth factor receptor (cMET/MET) targeted therapies for developing new and robust predictive biomarkers in oncology.

Original languageEnglish (US)
Pages (from-to)100863-100898
Number of pages36
JournalOncotarget
Volume8
Issue number59
DOIs
StatePublished - Jan 1 2017

Fingerprint

Fluorescence In Situ Hybridization
Biomarkers
Immunohistochemistry
Molecular Targeted Therapy
Proto-Oncogene Proteins c-met
Fibroblast Growth Factor Receptors
Neoplasms
United States Food and Drug Administration
Epidermal Growth Factor Receptor
Therapeutics
Medicine
Pathology
Ligands
Technology
Polymerase Chain Reaction
Pharmaceutical Preparations
Population

Keywords

  • Biomarker
  • FISH
  • IHC
  • Predictive
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

@article{10fdfee263a94a969f5bbaba34220b99,
title = "Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?",
abstract = "Molecular techniques have improved our understanding of the pathogenesis of cancer development. These techniques have also fueled the rational development of targeted drugs for patient populations stratified by their genetic characteristics. These novel methods have changed the classic paradigm of diagnostic pathology; among them are IHC, FISH, polymerase chain reaction (PCR) and microarray technology. IHC and FISH detection methods for human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR) and programmed death ligand-1 (PD-L1) were recently approved by the Food and Drug Administration (FDA) as routine clinical practice for cancer patients. Here, we discuss general challenges related to the predictive power of these molecular biomarkers for targeted therapy in cancer medicine. We will also discuss the prospects of utilizing new biomarkers for fibroblast growth factor receptor (FGFR) and hepatocyte growth factor receptor (cMET/MET) targeted therapies for developing new and robust predictive biomarkers in oncology.",
keywords = "Biomarker, FISH, IHC, Predictive, Targeted therapy",
author = "Chae, {Young Kwang} and Ayush Arya and Lauren Chiec and Hiral Shah and Ari Rosenberg and Sandip Patel and Kirtee Raparia and Jaehyuk Choi and Wainwright, {Derek A.} and Victoria Villaflor and Massimo Cristofanilli and Francis Giles",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19809",
language = "English (US)",
volume = "8",
pages = "100863--100898",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "59",

}

Challenges and future of biomarker tests in the era of precision oncology : Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? / Chae, Young Kwang; Arya, Ayush; Chiec, Lauren; Shah, Hiral; Rosenberg, Ari; Patel, Sandip; Raparia, Kirtee; Choi, Jaehyuk; Wainwright, Derek A.; Villaflor, Victoria; Cristofanilli, Massimo; Giles, Francis.

In: Oncotarget, Vol. 8, No. 59, 01.01.2017, p. 100863-100898.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Challenges and future of biomarker tests in the era of precision oncology

T2 - Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

AU - Chae, Young Kwang

AU - Arya, Ayush

AU - Chiec, Lauren

AU - Shah, Hiral

AU - Rosenberg, Ari

AU - Patel, Sandip

AU - Raparia, Kirtee

AU - Choi, Jaehyuk

AU - Wainwright, Derek A.

AU - Villaflor, Victoria

AU - Cristofanilli, Massimo

AU - Giles, Francis

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Molecular techniques have improved our understanding of the pathogenesis of cancer development. These techniques have also fueled the rational development of targeted drugs for patient populations stratified by their genetic characteristics. These novel methods have changed the classic paradigm of diagnostic pathology; among them are IHC, FISH, polymerase chain reaction (PCR) and microarray technology. IHC and FISH detection methods for human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR) and programmed death ligand-1 (PD-L1) were recently approved by the Food and Drug Administration (FDA) as routine clinical practice for cancer patients. Here, we discuss general challenges related to the predictive power of these molecular biomarkers for targeted therapy in cancer medicine. We will also discuss the prospects of utilizing new biomarkers for fibroblast growth factor receptor (FGFR) and hepatocyte growth factor receptor (cMET/MET) targeted therapies for developing new and robust predictive biomarkers in oncology.

AB - Molecular techniques have improved our understanding of the pathogenesis of cancer development. These techniques have also fueled the rational development of targeted drugs for patient populations stratified by their genetic characteristics. These novel methods have changed the classic paradigm of diagnostic pathology; among them are IHC, FISH, polymerase chain reaction (PCR) and microarray technology. IHC and FISH detection methods for human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR) and programmed death ligand-1 (PD-L1) were recently approved by the Food and Drug Administration (FDA) as routine clinical practice for cancer patients. Here, we discuss general challenges related to the predictive power of these molecular biomarkers for targeted therapy in cancer medicine. We will also discuss the prospects of utilizing new biomarkers for fibroblast growth factor receptor (FGFR) and hepatocyte growth factor receptor (cMET/MET) targeted therapies for developing new and robust predictive biomarkers in oncology.

KW - Biomarker

KW - FISH

KW - IHC

KW - Predictive

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85034638288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034638288&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19809

DO - 10.18632/oncotarget.19809

M3 - Review article

C2 - 29246028

AN - SCOPUS:85034638288

VL - 8

SP - 100863

EP - 100898

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 59

ER -